Cagrilintide Acetate 10 mg

Buy Cagrilintide Acetate 10 mg – Dragon Pharma Peptide for Weight Loss & Appetite Control

Dragon Pharma Cagrilintide is a synthetic amylin analog peptide designed to regulate appetite, delay gastric emptying, and support weight loss in obese or overweight individuals. With its 10 mg lyophilized formulation, this research-grade compound mimics the natural effects of amylin, a hormone co-secreted with insulin that plays a crucial role in satiety and metabolic balance.

What Is Cagrilintide?

Cagrilintide is a long-acting amylin receptor agonist that helps regulate appetite by acting on brain centers responsible for satiety. It works synergistically with GLP-1 analogs and has demonstrated promising results for managing obesity, particularly in combination with Dragon Pharma Semaglutide.

According to a 2025 clinical study published in NEJM, Cagrilintide showed significant reductions in body weight and appetite when administered weekly, making it one of the most exciting peptide therapies for obesity research today.

Benefits of Dragon Pharma Cagrilintide

• Supports consistent weight loss and fat reduction
• Delays gastric emptying and promotes fullness
• Complements GLP-1 analogs like Semaglutide
• Reduces hunger and food cravings
• Long-acting injectable peptide (weekly administration)

How to Use Cagrilintide Acetate

Supplied as a lyophilized 10 mg peptide, Dragon Pharma's Cagrilintide should be reconstituted with bacteriostatic water before subcutaneous injection. Typical research dosing begins at 0.1 mg to 0.4 mg per week, adjusted based on tolerance and observed effects. Due to its long half-life, once-weekly administration is common.

For synergistic benefits, it is often paired with GLP-1 receptor agonists. Many research subjects also stack it with GHK-Cu or CJC-1295 DAC for improved body composition and recovery support.

Who Should Consider Cagrilintide?

This compound is intended for researchers studying:

• Weight loss and metabolic regulation
• Appetite suppression and gastric motility
• Anti-obesity therapies
• Synergistic effects with GLP-1 peptides

Lab Quality Results

Lab-tested on September 13, 2024, Dragon Pharma's Cagrilintide was confirmed to contain 9.39 mg per vial with a purity of 99.790%, making it one of the most consistent amylin analogs available for research in the USA.

Legal Status and Research Use

Cagrilintide is not currently FDA-approved for human use. However, it is legally available for research purposes only in the United States. You can obtain it through reputable sources such as this supplier of Dragon Pharma Cagrilintide.

Stacking Options

Researchers often combine Cagrilintide with:

• Melanotan 2 – for additional appetite suppression and energy balance
• PT-141 – for mood and libido modulation during restrictive diets
• Anavar 50 mg – for lean mass preservation during caloric deficits

Side Effects and Safety

Cagrilintide may cause mild nausea, delayed gastric emptying, or constipation, especially during initial dosing. These effects typically subside within a few days. It has not shown hepatotoxic or androgenic activity and does not interfere with other hormonal pathways.

Why Choose Dragon Pharma?

Dragon Pharma continues to lead the research peptide market with consistently dosed, lab-verified compounds. Their 10 mg Cagrilintide Acetate formulation ensures purity, reliability, and proper lyophilization protocols to preserve integrity until reconstitution. For additional weight loss and metabolic support peptides, explore the full Dragon Pharma peptide catalog.

Frequently Asked Questions